Free Trial

Justices reject Johnson & Johnson appeal of $2B talc verdict

In this April 15, 2011, file photo, a bottle of Johnson's baby powder is displayed. Johnson & Johnson is asking for Supreme Court review of a $2 billion verdict in favor of women who claim they developed ovarian cancer from using the company's talc products. (AP Photo/Jeff Chiu, File)

WASHINGTON (AP) — The Supreme Court is leaving in place a $2 billion verdict in favor of women who claim they developed ovarian cancer from using Johnson & Johnson talc products.

The justices did not comment Tuesday in rejecting Johnson & Johnson's appeal. The company argued that it was not treated fairly in facing one trial involving 22 cancer sufferers who came from 12 states and different backgrounds.

A Missouri jury initially awarded the women $4.7 billion, but a state appeals court dropped two women from the suit and reduced the award to $2 billion. The jury found that the company’s talc products contain asbestos and asbestos-laced talc can cause ovarian cancer. The company disputes both points.

Johnson & Johnson, which is based in New Brunswick, New Jersey, has stopped selling its iconic talc-based Johnson’s Baby Powder in the U.S. and Canada, though it remains on the market elsewhere.

Justices Samuel Alito and Brett Kavanaugh took no part in the court's action. Alito owns $15,000 to $50,000 in Johnson & Johnson stock. Kavanaugh's father headed the trade association that lobbied against labeling talc a carcinogen and including a warning label on talc products.

Ethicists contacted by The Associated Press said they did not think E. Edward Kavanaugh's role required his son to step aside from the case.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.717 of 5 stars
$156.09+1.1%3.33%23.47Moderate Buy$171.82
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines